𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer

✍ Scribed by Nina N. Nupponen; Mika J. Wallén; Damaris Ponciano; Christiane M. Robbins; Teuvo L.J. Tammela; Robert L. Vessella; John D. Carpten; Tapio Visakorpi

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
102 KB
Volume
39
Category
Article
ISSN
1045-2257

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Three putative prostate cancer–susceptibility genes, RNASEL/HPC1 at 1q24, MSR1 at 8p22, and ELAC2/HPC2 at 17p11, have recently been identified. Our objective was to investigate somatic mutations in these genes in sporadic prostate cancer. We analyzed 39 clinical prostate cancer specimens, 10 prostate cancer xenografts (LuCaP series), and 4 prostate cancer cell lines (LNCaP, DU145, PC‐3, and MPC‐3) for genetic changes using denaturing high‐performance liquid chromatography and direct sequencing in order to screen the whole coding regions of RNASEL and MSR1, as well as exons 7 and 17 of ELAC2. The known 471delAAAG truncating mutation was found in the RNASEL gene in cell line LNCaP. The only new missense variation in RNASEL, Gly296Val, was found in cell line DU145, but not in any other samples. RNASEL and ELAC2 also showed the common missense polymorphic changes. A previously reported truncating mutation (Arg293X) was found in MSR1 in the germ line of one individual. Our results indicate that inactivation of the RNASEL, ELAC2, or MSR1 genes by somatic mutation is a rare phenomenon in sporadic prostate cancer. © 2003 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Analysis of breast cancer susceptibility
Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer
✍ Pimpicha Patmasiriwat; Kris Bhothisuwan; Olga M. Sinilnikova; Sandrine Chopin; S 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB 👁 2 views

Here we report the study on BRCA1 and BRCA2 mutations in 12 Thai breast and/or ovarian cancer families and 6 early-onset breast or breast/ovarian cancer cases without a family history of cancer. Five distinct rare alterations were identified in each gene: four introducing premature stop codons, one

Mutation analysis of the BRCA1 and BRCA2
Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 Flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease
✍ Kathleen Claes; Eva Machackova; Michel De Vos; Geert Mortier; Anne De Paepe; Lud 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 41 KB 👁 2 views

Germline mutations within the adenomatous polyposis coli (APC) gene, a tumor suppressor gene, are responsible for most cases of familial adenomatous polyposis (FAP), an autosomal dominantly inherited predisposition to colorectal cancer. To date, more than 300 germ-line causative mutations within thi

Mutation analysis of the MLH1, MSH2 and
Mutation analysis of the MLH1, MSH2 and MSH6 genes in patients with double primary cancers of the colorectum and the endometrium: A population-based study in northern Sweden
✍ Kristina Cederquist; Monica Emanuelsson; Ingela Göransson; Elke Holinski-Feder; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 105 KB 👁 2 views

## Abstract Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominant disorder that predisposes to predominantly colorectal and endometrial cancers due to germline mutations in DNA mismatch repair genes, mainly __MLH1__, __MSH2__ and in families with excess endometrial cancer also

Erratum to Cederquist et al., “Mutation
Erratum to Cederquist et al., “Mutation analysis of the MLH1, MSH2 and MSH6 genes in patients with double primary cancers of the colorectum and the endometrium—A population-based study in northern Sweden.” Int J Cancer 2004; 109(3):370–376
📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 27 KB 👁 1 views

## Abstract The original article to which this Erratum refers was published in International Journal of Cancer (2004) 109(3) 370–376DOI: 10.1002/ijc.11718